5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

Serotonin (5-hydroxytryptamine; 5-HT) 2A receptor (5-HT2AR) signaling is essential for the actions of classical psychedelic drugs. In this study, we examined whether sequence variations in the 5-HT2AR gene affect the signaling of four commonly used psychedelic drugs. We examined the in vitro pharmacology of seven non-synonymous single-nucleotide polymorphisms (SNPs), which give rise to Ser12Asn, Thr25Asn, Asp48Asn, Ile197Val4.47, Ala230Thr, Ala447Val, and His452Tyr variant 5-HT2A serotonin receptors. We found that these non-synonymous SNPs exert statistically significant, although modest, effects on the efficacy and potency of four therapeutically relevant psychedelics. Significantly, the in vitro pharmacological effects of the SNP drug actions at 5-HT2AR are drug specific.

5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics

Excerpts from the publication

Read more

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database